# What did the March 2026 PBAC decide on tirzepatide? Updated 2026-10-15. The March 2026 Pharmaceutical Benefits Advisory Committee (PBAC) outcomes record a recommendation to list tirzepatide for adults with inadequately controlled type 2 diabetes mellitus. The entry follows a July 2025 deferral and names Eli Lilly Australia as the sponsor. These are facts from the March 2026 decision, read on 15 October 2026; the entry does not state an effective PBS listing date. | | | | --- | --- | | Decision record | PBAC meeting outcomes, March 2026, pages 47-48 | | Recorded outcome | Recommended | | Named substance | Tirzepatide (March 2026 PBAC outcomes) | | Scope of recommendation | Adults with inadequately controlled type 2 diabetes mellitus (March 2026 PBAC outcomes) | | Publication page updated | 13 May 2026 (PBS publication page) | | Source read | 15 October 2026 | A committee outcome has its own date and scope. Pages 47-48 of the March 2026 PBAC outcomes record the tirzepatide decision and identify the sponsor as Eli Lilly Australia (read 15 October 2026). ## What outcome does the March 2026 record give? The [March 2026 PBAC outcomes](https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-03/pbac-web-outcomes-03-2026-v3.pdf) mark tirzepatide as Recommended for adults with inadequately controlled type 2 diabetes mellitus. The entry identifies a resubmission following the July 2025 deferral and names Eli Lilly Australia as sponsor. Pages 47-48 contain the decision and its continuation, checked on 15 October 2026. This decision summary belongs to [Peptides and Australian Law](/learn/peptides-and-australian-law). The [Schedule 4 explainer](/learn/peptides-and-australian-law/what-schedule-4-and-appendix-d-mean) covers the separate scheduling record. The [November 2025 semaglutide decision](/learn/peptides-and-australian-law/semaglutide-pbac-november-2025-status) has its own meeting date and scope. ## Does this decision state an effective PBS listing date? The tirzepatide row in the [March 2026 PBAC outcomes](https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-03/pbac-web-outcomes-03-2026-v3.pdf) does not state an effective PBS listing date. The [publication page](https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-march-2026) identifies the meeting as March 2026 and gives 13 May 2026 as its update date. This page records that decision, checked on 15 October 2026, rather than asserting a later listing outcome. A separate [SURMOUNT programme design paper](https://doi.org/10.1002/oby.23612) appeared in *Obesity* in January 2023; it describes the tirzepatide trial programme, not this March 2026 committee decision (le Roux et al., 2023). The [TRIUMPH-OUTCOMES status record](/learn/peptides-and-australian-law/retatrutide-triumph-outcomes-status) concerns a different trial registry entry. ## Frequently asked questions ### Was the March 2026 tirzepatide decision a recommendation? Yes. The [March 2026 PBAC outcomes](https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-03/pbac-web-outcomes-03-2026-v3.pdf), pages 47-48, mark tirzepatide as Recommended for the specified type 2 diabetes population (read 15 October 2026). ### Does the decision give a PBS commencement date? The tirzepatide entry in the [March 2026 PBAC outcomes](https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-03/pbac-web-outcomes-03-2026-v3.pdf) states no effective PBS listing date (pages 47-48, read 15 October 2026). ## Citations - le Roux CW, Zhang S, Aronne LJ, et al.. Obesity. 2023;31:96-110. SURMOUNT clinical development programme: rationale and design. DOI: 10.1002/oby.23612 --- Canonical page: https://www.formlaboratories.com/learn/peptides-and-australian-law/tirzepatide-pbac-march-2026-status Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide. - Site guide for agents: https://www.formlaboratories.com/llms.txt - Sitemap: https://www.formlaboratories.com/sitemap.xml - Full catalogue: https://www.formlaboratories.com/shop - Contact: hello@formlaboratories.com All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.